A complete response rate of 85.1% in relapsed or refractory B-cell non-Hodgkin lymphoma, sustained over a median follow-up of nearly 54 months, is the number AbelZeta is betting its U.S. clinical strategy on. The company announced FDA clearance of an IND for Prizloncabtagene Autoleucel (Prizlon-cel), its anti-CD20/CD19 bispecific CAR-T, in large B-cell lymphoma. The clearance follows AbelZeta’s move just last month to reclaim full global rights to the asset from Janssen Biotech, which had held a collaboration and license agreement for the program since May 2023. That sequence matters: the company enters U.S. clinical development with rights fully consolidated and a dataset already in hand, rather than building toward a future readout with a partner at the table.
The early clinical data, drawn from 48 patients enrolled in China-based trials and presented at EBMT in March 2026, reported an overall response rate of 91.5% and a median progression-free survival of 60.1 months. Those figures come from a broad r/r B-cell NHL population, not a LBCL-only subset, so direct comparison to approved single-target CAR-T benchmarks in the same line requires caution. Still, the durability is notable. Yescarta (axicabtagene ciloleucel), an approved CD19-targeting CAR-T, is now used as early as the second-line setting. The competitive ceiling for a new entrant is therefore defined by depth of response and durability in patients who have already failed CAR-T, a population where approved options remain limited and retreatment strategies are largely off-label.
AbelZeta is pursuing two parallel U.S. paths: third-line or later patients who have previously received CAR-T therapy, and second-line patients who are CAR-T naive. That dual-cohort design is strategically deliberate. The post-CAR-T population is smaller and harder to treat, but it is essentially unaddressed by existing cell therapies; bispecific targeting of both CD20 and CD19 is the mechanistic argument for why Prizlon-cel might work where prior CD19-directed therapies have failed. The CAR-T-naive second-line cohort is the larger commercial opportunity, and it positions the asset to compete in a market that, across the non-Hodgkin lymphoma segment alone, represents the majority of a global CAR-T market projected at nearly $11 billion in 2026. A registrational Phase 2 in CAR-T-naive LBCL patients is already running in China, which gives AbelZeta a potential data bridge if regulators allow cross-referencing.
The single metric worth tracking from here is the U.S. protocol finalization for the post-CAR-T cohort. FDA’s willingness to accept response rate as a primary endpoint in that heavily pretreated population, rather than demanding a randomized comparator arm, will determine whether Prizlon-cel can reach approval on a compressed evidence burden or faces a far longer and more expensive path to U.S. commercialization.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
